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OBJECTIVE—Nonalcoholic fatty liver disease (NAFLD) is
linked to obesity and diabetes, suggesting an important role of
adipose tissue in the pathogenesis of NAFLD. Here, we aimed to
investigate the interaction between adipose tissue and liver in
NAFLD and identify potential early plasma markers that predict
nonalcoholic steatohepatitis (NASH).
RESEARCH DESIGN AND METHODS—C57Bl/6 mice were
chronically fed a high-fat diet to induce NAFLD and compared
with mice fed a low-fat diet. Extensive histological and pheno-
typical analyses coupled with a time course study of plasma
proteins using multiplex assay were performed.
RESULTS—Mice exhibited pronounced heterogeneity in liver
histological scoring, leading to classiﬁcation into four subgroups:
low-fat low (LFL) responders displaying normal liver morphol-
ogy, low-fat high (LFH) responders showing benign hepatic
steatosis, high-fat low (HFL) responders displaying pre-NASH
with macrovesicular lipid droplets, and high fat high (HFH)
responders exhibiting overt NASH characterized by ballooning of
hepatocytes, presence of Mallory bodies, and activated inﬂam-
matory cells. Compared with HFL responders, HFH mice gained
weight more rapidly and exhibited adipose tissue dysfunction
characterized by decreased ﬁnal fat mass, enhanced macrophage
inﬁltration and inﬂammation, and adipose tissue remodeling.
Plasma haptoglobin, IL-1, TIMP-1, adiponectin, and leptin were
signiﬁcantly changed in HFH mice. Multivariate analysis indi-
cated that in addition to leptin, plasma CRP, haptoglobin,
eotaxin, and MIP-1 early in the intervention were positively
associated with liver triglycerides. Intermediate prognostic
markers of liver triglycerides included IL-18, IL-1, MIP-1, and
MIP-2, whereas insulin, TIMP-1, granulocyte chemotactic protein
2, and myeloperoxidase emerged as late markers.
CONCLUSIONS—Our data support the existence of a tight
relationship between adipose tissue dysfunction and NASH
pathogenesis and point to several novel potential predictive
biomarkers for NASH. Diabetes 59:3181–3191, 2010
O
besity is associated with a number of metabolic
perturbations that increase risk for type 2 dia-
betes, coronary heart disease, and liver dys-
function. These metabolic perturbations,
collectively referred to as the metabolic syndrome, include
hypertension, dyslipidemia, and insulin resistance. Addi-
tionally, metabolic syndrome is often characterized by
nonalcoholic fatty liver disease (NAFLD) (1).
It is evident that obesity represents a state of chronic
low-grade inﬂammation that likely originates in the adi-
pose tissue. Upon fat expansion, macrophages and other
leukocytes inﬁltrate the adipose tissue and account for
secretion of various cytokines and adipokines (2,3). Be-
cause many of these cytokines reduce insulin sensitivity,
the elevated inﬂammatory status may provide a mechanis-
tic explanation for the well-established link between
obesity and insulin resistance (4). Alternatively, the com-
plications of obesity may be traced to aberrant storage of
lipids in nonadipose tissues, which can profoundly disturb
organ function (5).
Excess storage of fat in liver is the hallmark of NAFLD,
which refers to a wide histological spectrum of liver
diseases ranging from hepatic steatosis to pathological
nonalcoholic steatohepatitis (NASH) and ﬁbrotic compli-
cations (6). Steatosis alone is considered relatively innoc-
uous, but prognosis is much more grim for NASH, which
might progress to cirrhosis and liver cancer (7). Several
theories have been proposed to explain why steatosis
occasionally progresses to NASH. One popular model is
the two-hit hypothesis, in which the ﬁrst hit is the accu-
mulation of fat in the hepatocytes that renders the liver
more susceptible to second hits comprised of inﬂamma-
tory insults or oxidative stress (7). Alternatively, progres-
sion of steatosis to NASH may be stimulated by cellular
lipotoxicity mediated by lipotoxic fatty acids, cholesterol,
and/or ceramides (8).
Since NAFLD is strongly linked to obesity, an important
role of adipose tissue in the pathogenesis of NAFLD is
suspected. Indeed, growing evidence indicates that pro-
teins secreted from adipose tissue may be implicated in
NAFLD (9). To gain insight into the nature of the interac-
tion between adipose tissue and liver in the context of
obesity-related NAFLD and to identify potential early
plasma markers that predict steatosis and/or NASH, we
subjected C57Bl/6 mice to a chronic high-fat diet to induce
NAFLD and coupled extensive histological and phenotyp-
ical analyses with a time course study of plasma proteins
using multiplex assay. The results indicate a tight relation-
ship between adipose tissue dysfunction and NASH patho-
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biomarkers for NASH.
RESEARCH DESIGN AND METHODS
Twenty male C57BL/6JOlaHsd (C57Bl/6) mice at 8 weeks of age were purchased
from Harlan (Horst, the Netherlands) and housed individually. Detailed informa-
tion about the mouse strain is available at the following Web site: http://www.
harlan.com/research_models_and_services/research_models_by_product_type/
inbred_mice/c57bl6j_inbred_mice.hl. After 3 weeks on a low-fat diet (LFD),
mice were divided into two weight-matched groups. One group continued on
the LFD while the other group switched to a high fat diet (HFD) containing 10
or 45% energy as triglycerides, respectively (D12450B and D12451; Research
Diets) for 21 weeks. Lard in these diets was replaced by palm oil. Palm oil is
devoid of cholesterol, which may have proinﬂammatory properties. Food
intake was measured by weighing the pellets once per week. Mice were
housed individually, allowing for assessment of food consumption of individ-
ual mice. Food intake was averaged over the 20-week intervention and
multiplied by the caloric value of the feed to determine energy intake in kcal
 mouse
1  day
1. Numbers were subsequently averaged per group. At weeks
0, 2, 4, 8, 12, 16, and 20, tail vein plasma samples were collected after a 6-h fast.
Two mice within the HFD group died before the end of the experiment for
reasons unrelated to the dietary intervention. After 21 weeks, ad libitum–fed
mice were anesthetized using isoﬂuorane. Blood was collected by orbital
puncture, followed by sacriﬁce via cervical dislocation. Liver and epididymal
white adipose tissues were removed, weighed, and immediately frozen in
liquid nitrogen. For histology, liver was frozen with OCT compound, and
adipose tissue samples were ﬁxed in 10% formalin and processed for parafﬁn
embedding. Animal experiments were approved by the local animal ethics
committee at Wageningen University.
Hepatic triglyceride content determination, RNA extraction, real-time
PCR, and Affymetrix Microarrays. Liver triglycerides were determined
enzymatically as previously described (10). Other techniques were employed
as previously described (11). Microarray data were analyzed as previously
described (12). Genes with a P value 0.05 were considered signiﬁcantly
regulated. Array data have been submitted to the Gene Expression Omnibus
(accession no. GSE24031). Gene set enrichment analysis was used to identify
signiﬁcantly regulated pathways (13). Gene sets with a false discovery rate
0.25 were considered signiﬁcant.
Plasma measurements. Plasma concentrations of multiple chemokines were
measured with multiplex technologies (Rodent Map 2.0; Rules Based Medi-
cine, Austin, TX). Plasma free fatty acids and alanine aminotransferase were
measured with commercially available kits from Instruchemie (Delfzijl, the
Netherlands). Plasma leptin and insulin levels were measured using kits from
Linco (St. Louis, MO).
Liver immunohistochemistry. For oil red O staining, 5 m frozen liver
sections were air-dried for 30 min, followed by ﬁxation in formal calcium (4%
formaldehyde and 1% CaCl2). Oil red O staining was performed using standard
protocols. Hematoxylin-eosin (H-E) staining of frozen liver sections was
carried out as described at http://www.ihcworld.com/histology.htm. Collagen
was stained using fast green FCF/sirius red F3B.
For immunohistochemistry, 5 m frozen liver sections were cut, dried
overnight, ﬁxed in acetone for 10 min, and washed in PBS prior to use. For
visualization of hepatic stellate cell activation, rabbit anti–glial ﬁbrillary acidic
protein (GFAP) polyclonal antibody was used (Dako, Glostrup, Denmark).
For detection of macrophages/monocytes, a rat polyclonal anti-Cd68 antibody
(Serotec, Oxford, U.K.) was used. Sections were incubated for 30 min at
room temperature with GFAP (1:1,000 dilution) or Cd68 (1:100 dilution)
primary antibodies, followed by incubation for 30 min at room temperature
with anti-rabbit peroxidase-conjugated En Vision (GFAP; Dako) or 1:20
diluted anti-rat IgG peroxidase-conjugated secondary antibodies (Cd68; Sero-
tec). Visualization of the complex was done using 3-amino-9-ethylcarbazole
chromogen for 15 min, followed by staining with H-E. Negative controls were
performed by omitting the primary antibody.
Immunohistochemistry of adipose tissue. 5-m-thick parafﬁn-embedded
sections were cut, dried for 30 min at 37°C, and washed in PBS prior to use.
Staining of adipose tissue macrophages was carried out using an antibody
against Cd68 as described above. H-E staining of sections was done using
standard protocols. Collagen was stained using fast green FCF/sirius red F3B.
Multivariate Rules-Based Medicine data analysis. The data obtained from
the commercial Rules-Based Medicine multiplex analysis (70 proteins mea-
sured in 126 plasma samples) contained a number of technically unreliable
entries for speciﬁc samples and proteins that were: 1) lower than the least
detectable dose (LDD): replaced by 0.5  LDD, 2) not detectable (i.e., not
measured on the standard curve): replaced by 0.1  LDD, or 3) not
measurable (i.e., not sufﬁcient sample material available): replaced by 0.1 
LDD. Proteins were removed if they did not contain more than 50% reliable
entries for two or more groups of the totally available 14 groups (7 time
points  2 diets). This approach assures that potentially relevant group
differences are retained in the data. Of the 70 proteins screened, 19 were
excluded, 18 contained more than 50% reliable entries for at least two groups,
and 33 proteins contained 100% reliable entries for all groups. One mouse was
removed from the dataset for multivariate analysis on the basis that some
plasma proteins display atypical outlying values.
Multiway partial least squares (PLS) (MPLS) is a multivariate statistical
technique that is an extension of standard PLS analysis able to analyze data
across different time points (14–16). Both methods are able to analyze large
numbers of variables in small sample sizes by reducing the dimensionality of
the data. In contrast to standard two-dimensional data (matrix), multiway data
can be represented as a collection of matrices (a cube) where each matrix
contains data from one speciﬁc time point. For MPLS, the data were centered
across the samples (i.e., zero mean) to remove offsets followed by autoscaling
for the variables (i.e., a mean  SD of 0  1 to remove arbitrary differences
in measurement scales [16]).
Validation of the MPLS models using a double cross-validation strategy and
the selection of most important proteins from the models have been per-
formed as previously described (17). Because (double) cross-validation relies
on a random subdivision of data, the complete validation procedure was
repeated ﬁve times on the basis of different random subdivisions of the data
during cross-validation. A model was considered to be reliable if at least four
(out of ﬁve) models could be calculated with an R
2 	 0.7.
Statistical analyses. Statistically signiﬁcant differences were calculated
using Student’s T test. The cutoff for statistical signiﬁcance was set at P 
0.05. MPLS was performed using the N-way toolbox (http://www.models.life.
ku.dk/nwaytoolbox) in combination with Matlab, version 7.1.0, release 14
(The Mathworks, Natick, MA) and homemade software.
RESULTS
Development of NASH in a subpopulation of C57Bl/6
mice fed a HFD. To study the effect of chronic high-fat
feeding on liver metabolic functions, C57Bl/6 mice were
fed an LFD or HFD for 21 weeks. Mice fed the HFD gained
more weight compared with mice fed the LFD (Fig. 1A),
which was already evident after 2 weeks. Enhanced
weight gain in mice fed a HFD may be related to increased
energy intake (Fig. 1B). After 21 weeks, weight of the
epididymal fat pad, which was assumed to reﬂect overall
adiposity of the animals, was markedly higher in mice fed
an HFD (Fig. 1C).
To characterize the effect of an HFD on hepatic steato-
sis, liver sections were stained with H-E (Fig. 1D) and oil
red O (Fig. 1E). Remarkably, a marked heterogeneity in fat
accumulation and histology was observed within each
group. Scoring of the sections by a pathologist (T.R.)
indicated different stages of NAFLD and led to classiﬁca-
tion of mice into four subgroups, which surprisingly but
not deliberately ended up being of approximately equal
size. These subgroups were low-fat low (LFL) responders
(n 
 4), which display normal liver morphology; low-fat
high (LFH) responders (n 
 6), which develop benign
hepatic steatosis; high-fat low (HFL) responders (n 
 4),
which show a pre-NASH phenotype of macrovesicular
lipid droplets; and high-fat high (HFH) responders (n 
 4),
which develop overt NASH characterized by ballooning of
hepatocytes, presence of Mallory bodies, and activated
inﬂammatory cells (Fig. 1D).
Quantitation of hepatic triglycerides conﬁrmed the het-
erogeneity between the subgroups, with HFH mice accu-
mulating the highest amount of triglycerides (Fig. 1F).
Consequently, liver–to–body weight ratio was increased
speciﬁcally in HFH mice, indicating hepatomegaly (Fig.
1G). Finally, plasma alanine aminotransferase activity was
highest in the HFH subgroup, reﬂecting increased liver
damage (Fig. 1H).
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impaired in HFH Responders. To correlate changes in
liver functions with gene expression, expression proﬁl-
ing was performed on individual mouse livers. Microar-
ray data were processed according to subgroups, with
LFL mice serving as the reference group for calculation
of fold change and P values. The most dramatic effects
were observed in HFH responders as shown by changes
in expression of 	3,000 genes (Fig. 2A). To identify
genes regulated exclusively in HFH responders, we
selected genes that were statistically signiﬁcantly regu-
lated in HFH versus all subgroups but unchanged in
other comparisons. This HFH responder gene expres-
sion signature comprised 388 upregulated and 319
downregulated genes. One dominant pathway within the
HFH expression signature was lipid metabolism, illus-
trated by the marked induction of Cidec and Mogat1
(Fig. 2B). Other lipid metabolism genes such as Cd36
and Ppar increased gradually from LFL to HFH, corre-
lating with hepatic triglycerides (Fig. 1F and Fig. 2B).
Another pathway well represented within the HFH
expression signature was inﬂammation, as shown by
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FIG. 1. A subpopulation of mice fed an HFD develops NASH. A: Changes in body weight in C57Bl/6 mice fed an LFD (;n 10) or HFD (f;n
8). B: Mean energy intake of mice fed an LFD or HFD during 21 weeks of dietary intervention. C: Weight of epididymal fat pad after 21 weeks
of dietary intervention. Error bars reﬂect SD. *Signiﬁcantly different from mice fed an LFD according to Student’s t test (P < 0.05). H-E staining
(D) and oil red O staining (E) of representative liver sections of the four subgroups (LFL, LFH, HFL, and HFH). F: liver triglyceride
concentration. G: Liver weight (expressed as percentage of total body weight [BW]). H: Activity of alanine aminotransferase (ALT) (glutamate
pyruvate transaminase) in plasma. Error bars reﬂect SD. Bars with different letters are statistically different (P < 0.05 according to Student’s
t test). n  4 mice per group for LFL, HFL, and HFH, and n  6 mice per group for LFH. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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encoding orosomucoid, serum amyloid-A, and lipoca-
lin-2 in the HFH subgroup (Fig. 2B), and conﬁrmed by
quantitative PCR (Fig. 2C). Finally, many genes in the
HFH expression signature were related to ﬁbrosis, in-
cluding Ctgf, collagens, metalloproteases, and Timp1
(Fig. 2B and C). Expression analysis of individual mice
within the HFH group showed uniform induction of
genes involved in the above-mentioned pathways (Fig.
2B). Gene set enrichment analysis indicated that while
pathways related to lipid metabolism were upregulated in
all subgroups when compared with LFL mice, with most
prominent effects observed in HFH mice, numerous path-
ways of inﬂammation, cell cycle, and oxidative stress were
speciﬁcally induced in HFH mice (supplemental Table 1,
available in an online appendix [available at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0224/DC1]). The
complete microarray dataset is available at http://
humannutrition2.wur.nl/duval2010.
The elevated inﬂammatory status in HFH livers was
corroborated by immunostaining for macrophage
marker Cd68 (Fig. 3A). Early ﬁbrosis was detected in
one HFH mouse (Fig. 3B). Finally, hepatic stellate
activation was demonstrated in HFH mice by GFAP
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FIG. 2. Upregulation of inﬂammatory and ﬁbrotic gene expression in HFH responder mice. A: Number of genes up- or downregulated in the various
subgroups in comparison with the LFL mice as determined by Affymetrix GeneChip analysis. Genes with a P value <0.05 were considered
signiﬁcantly regulated. B: Heat map showing changes in expression of selected genes involved in lipid metabolism, inﬂammation, and ﬁbrosis in
liver. Mean expression in LFL mice was set at 1. Gene expression changes in individual mice within the HFH group are shown on the right. C:
Changes in gene expression of selected genes as determined by real-time quantitative PCR. Mean expression in LFL mice was set at 100%. Error
bars reﬂect SD. Bars with different letters are statistically different (P < 0.05 according to Student’s t test). Number of mice per group: n  4
for the LFL, HFL, and HFH groups and n  6 for the LFH group.
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port induction of inﬂammation and ﬁbrosis in HFH
responders, indicating NASH.
HFH responder mice exhibit adipose tissue dysfunc-
tion. Mice classiﬁed as high responders also gained the
most body weight (Fig. 4A), likely related to increased
food intake (Fig. 4B). Indeed, a positive correlation was
found between ﬁnal body weight and hepatic triglycerides
(Fig. 4C). Remarkably, despite increased weight gain,
weight of the epididymal fat pad at sacriﬁce was markedly
lower in HFH compared with that in HFL mice (Fig. 4D).
As expected, leptin expression in adipose tissue mirrored
adiposity (Fig. 4E), which was also true for the plasma free
fatty acids (Fig. 4F). Evaluation of the morphology of the
epididymal fat pad in HFH mice after H-E staining revealed
atrophied adipocytes surrounded by inﬂammatory cells,
which were hardly observed in HFL responders (Fig. 4G).
Cd68 immunostaining indicated increased presence of
macrophages in HFH mice (Fig. 4H), which was supported
by gene expression of F4/80 and Cd68 (Fig. 5). In contrast,
expression of the anti-inﬂammatory adipokine adiponectin
was markedly reduced in HFH mice, as was resistin (Fig.
5). Interestingly, expression of adipogenic (Ppar and
Fabp4) and lipogenic (Dgat2, Srebp-1, and fatty acid
A
B
C
FIG. 3. (Immuno)histochemical staining conﬁrms enhanced inﬂammation and early ﬁbrosis in HFH mice. A: Immunohistochemical staining of
macrophage activation in representative liver sections of HFL (left panel) and HFH (right panel) mice using antibody against the speciﬁc
macrophage marker Cd68. B: Collagen staining using fast green FCF/sirius red F3B. C: Staining of stellate cell activation using antibody against
GFAP. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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lated in HFH mice compared with HFL mice, suggesting
adipose tissue dysfunction. Finally, collagen staining re-
vealed ﬁbrotic adipose tissue in HFH mice (Fig. 4I), which
was supported by increased expression of tissue inhibitor
of matrix metalloproteinases (Timp-1) (Fig. 5). These data
suggest that HFH responders, classiﬁcation of which is
entirely determined by liver histology, exhibit adipose
tissue dysfunction characterized by decreased fat mass,
enhanced macrophage inﬁltration, inﬂammation, and adi-
pose tissue remodelling.
Plasma biomarkers are signiﬁcantly associated with
liver triglycerides. To ﬁnd early biomarkers that may
predict NASH in C57Bl/6 mice and that may serve as
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Cd68. I: Collagen staining using fast green FCF/sirius red F3B. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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and NASH, plasma was collected at different time points of
diet intervention and assayed for 70 plasma proteins using
multiplex analysis. Levels of most plasma proteins were
not consistently different between the subgroups. One
exception was the acute phase protein haptoglobin, which
was elevated in HFH mice after 12 weeks of diet interven-
tion (Fig. 6A). Similarly, plasma levels of the ﬁbrosis
marker TIMP-1 started to deviate at week 12 and further
increased until the end. Remarkably, interleukin (IL)-1
and leptin levels were already elevated in HFH after 2
weeks and this pattern was maintained throughout the
intervention. Finally, plasma insulin levels indicated that
HFH mice became hyperinsulinemic from week 12, sug-
gesting development of insulin resistance.
To systematically screen for plasma biomarkers that
predict liver triglycerides, multivariate analysis was per-
formed using MPLS. The results of multivariate analysis
between plasma proteins at different time points and liver
triglycerides are depicted in Fig. 6B and supplemental
Table 2. In addition to leptin, plasma levels of C-reactive
protein (CRP), eotaxin, haptoglobin, and macrophage in-
ﬂammatory protein (MIP)-1 early in the intervention
were positively associated with liver triglycerides at 20
weeks. Intermediate prognostic markers of liver triglycer-
ides included IL-18, IL-1, MIP-1, and MIP-2, whereas
insulin, TIMP-1, GCP-2, and MPO emerged as late markers.
Throughout the diet intervention, highest regression coef-
ﬁcients were obtained for CRP, haptoglobin, leptin, and
IL-1 (supplemental Table 2). Adiponectin was not signif-
icantly associated with liver triglycerides. The complete
multivariate dataset is available at http://humannutrition2.
wur.nl/duval2010. Besides potentially serving as predictive
biomarkers of liver triglycerides, these proteins may pro-
vide a functional link between adipose tissue dysfunction
and NAFLD.
DISCUSSION
C57Bl/6 mice fed a HFD represent a popular animal model
for human obesity and insulin resistance. Despite devel-
opment of hepatic steatosis and other features of patients
with NAFLD (18), except for a recent report the model has
not been extensively used to study NAFLD (19). As
expected, high-fat feeding increased adipose tissue mass
and hepatic fat storage. Consistent with previous data
showing considerable variability in the obese and diabetic
phenotype (20,21), we observed marked heterogeneity in
body weight gain. Additionally, the magnitude of fat stor-
age and NAFLD scoring differed markedly between the
mice, giving rise to four well-distinguishable groups. De-
tailed histological and gene expression analysis indicated
that HFH mice exhibit NASH. Accordingly, detailed study
of these HFH responders may give novel insight into the
development and progression of NAFLD.
Although humans have no epididymal fat pads, we
studied epididymal adipose tissue because it represents
the most commonly used fat depot in mouse studies, is
easily accessible, can be accurately weighed, and is rela-
tively homogenous. Unfortunately, we did not have access
to dual-energy X-ray absorptiometry or magnetic reso-
nance imaging to be able to measure fat percentage, lean
body mass, or fat distribution. Remarkably, HFH mice,
despite showing the highest weight gain, had signiﬁcantly
less epididymal fat after 21 weeks compared with HFL
mice, which likely reﬂects differences in overall adiposity.
An important question is why there is an apparent limit to
the expansion of adipose tissue in HFH mice and, espe-
cially, what is the link with NASH. Obesity-related adipo-
cyte hypertrophy is known to be associated with adipose
inﬂammation characterized by inﬁltration of macrophages
and other leukocytes, appearance of so-called crown-like
structures, and increased expression of several inﬂamma-
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FIG. 5. Changes in adipose gene expression indicates adipose tissue
dysfunction. Adipose tissue mRNA expression of a selected group of
genes was determined by quantitative real-time PCR after 21 weeks of
dietary intervention. Mean expression in LFL mice was set at 100%.
Error bars reﬂect SD. *Signiﬁcantly different from HFL mice accord-
ing to Student’s t test (P < 0.05). Number of mice per group: n  4 for
LFL, HFL, and HFH and n  6 for LFH.
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FIG. 6. Plasma proteins as early predictive biomarker for NASH in C57Bl/6 mice. A: Plasma concentration of haptoglobin, TIMP-1, IL-1, leptin,
and insulin were determined by multiplex assay at speciﬁc time points during the 21 weeks of dietary intervention after a 6-h fast. White squares,
LFL; light-gray squares, LFH; dark-gray squares, HFL; black squares, HFH. Error bars reﬂect SD. *Signiﬁcantly different from HFL mice according
to Student’s t test (P < 0.05). Number of mice per group: n  4 for LFL, HFL, and HFH and n  6 for LFH. B: Graphs illustrating the result of
multivariate analysis showing the association of protein plasma concentrations at various time points with ﬁnal liver triglyceride content. The
absRSD is the absolute relative standard deviation: the standard deviation of the regression coefﬁcients divided by the absolute mean value of
the regression coefﬁcients. Signiﬁcant proteins display an inverse absRSD value higher than two (bold line indicates the inverse absRSD
threshold value of 2). w, weeks.
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develops during obesity is not clear, but a role of hyper-
trophy, hypoxia, and adipocyte cell death has been sug-
gested (23,24). Compared with HFL mice, adipose tissue of
HFH mice showed more pronounced inﬂammation as
shown by increased macrophage staining and expression
of inﬂammatory marker genes and increased collagen
staining, suggesting ﬁbrosis. Furthermore, decreased adi-
pocyte size and increased cell death were observed in HFH
mice. Since HFH mice are classiﬁed entirely based on liver
histology, these data indicate a strong link between inﬂam-
matory and morphological changes in adipose tissue and
progression of steatosis to NASH. Consequently, adipose
tissue failure or dysfunction may signal progression of
hepatic steatosis toward NASH. These data support the
previous suggestion that poor expansion of adipose tissue
mass due to remodeling contributes to hepatic steatosis
induced by high-fat feeding (23) and thereby strengthen an
emerging view that obesity starts to cause metabolic
problems when adipose tissue cannot fully meet demands
for additional storage, leading to fat accumulation in other
organs such as muscle, liver, and -cells and causing
lipotoxicity (25–27). The limited expandability of adipose
tissue may be related to adipose tissue ﬁbrosis and asso-
ciated disproportionate accumulation of extracellular ma-
trix components (22).
Multivariate longitudinal analysis of plasma proteins
yielded a number of candidates that may serve as prog-
nostic markers for NAFLD and NASH. In addition, these
proteins may provide insight into the functional link
between adipose tissue dysfunction and NAFLD. Besides
leptin, the best predictive markers were the acute phase
proteins CRP and haptoglobin and MIP-1 (Ccl3). Plasma
CRP was previously proposed as a diagnostic marker for
NASH (28). In one study, high-sensitivity CRP was signif-
icantly elevated in patients with NASH compared with that
in patients with only steatosis (29). Furthermore, high-
sensitivity CRP correlated with the severity of ﬁbrosis in
NASH. In another study, plasma CRP was not helpful in
diagnosis of NASH in severely obese patients, possibly
because adipose tissue contributes to plasma CRP in
obesity.
Hardly any data exist on the relation between plasma
haptoglobin and NASH. Haptoglobin was included in a
composite biomarker combining 13 parameters to predict
NASH (30). Interestingly, in a recent study plasma hapto-
globin showed a negative correlation with ﬁbrosis stage
(31). There are no reports on the association between
plasma MIP-1 and hepatic steatosis or NASH. However, it
was reported that MIP-1 mRNA in human liver is posi-
tively associated with liver fat (32).
Another good predictive marker for liver triglycerides
was IL-1. Plasma IL-1 levels were signiﬁcantly elevated
in HFH mice already after 2 weeks of HFD, probably
because of elevated production in adipose tissue. Re-
cently, we showed that IL-1 may promote steatosis in
mice by inhibiting PPAR activity (33). Whether adipose
tissue–derived IL-1 links adipose tissue dysfunction and
NASH requires further study.
Recent studies indicate that IL-18 promotes hepatic
steatosis in mice (34,35). Interestingly, patients with
NAFLD were found to have signiﬁcantly elevated plasma
IL-18 levels (36). According to our multivariate analysis,
plasma IL-18 from week eight onward was signiﬁcantly
associated with liver triglycerides. Overall, further re-
search into the potential use of plasma CRP, haptoglobin,
MIP-1, and possibly IL-1, eotaxin, and IL-18 as prognos-
tic biomarkers for NAFLD in humans is warranted.
One of the late biomarkers to emerge from our study
was TIMP-1. Speciﬁcally, plasma TIMP-1 levels started to
deviate in the HFH mice after 12 weeks of HFD. Since
TIMP-1 expression was increased in HFH mice in both
liver and adipose tissue, it is unclear which tissue primar-
ily contributes to increased plasma levels. TIMP-1 is used
extensively as a marker of ﬁbrosis related to viral hepatitis
(37). However, its use in the context of NAFLD is very
limited. According to our data, plasma TIMP-1 levels may
have potential as a biomarker for NASH. Consistent with
this notion, plasma TIMP-1 was recently shown to be a
valuable component of a composite predictive marker of
NASH in human (38).
An adipokine that has been extensively linked to NAFLD
is adiponectin (37,39). Besides its antisteatotic role
(38,40), adiponectin has potent anti-inﬂammatory effects
in liver (39). In humans, plasma adiponectin, either alone
or as ratio to plasma leptin (41), has shown promise as a
diagnostic marker for NASH, although it should be vali-
dated in larger cohorts of patients (9). In the present study,
plasma adiponectin was not signiﬁcantly associated with
liver triglycerides.
Overall, the best predictive marker for liver triglycer-
ides, which was also clearly elevated in HFH mice, was
leptin. Portal infusion with leptin was shown to increase
hepatic triglycerides in rats (42). Furthermore, leptin
appears to be one of the key regulators of inﬂammation
and progression to ﬁbrosis in NASH (43–46). Although
some studies have found elevated plasma leptin levels in
patients with NASH (47,48), other studies have not, thus
somewhat questioning the potential of plasma leptin as a
noninvasive marker for diagnosis of NASH in humans (49).
Hyperleptinemia in HFH mice is expected to decrease
food intake. However, energy intake was higher in HFH
compared with that in other subgroups, suggesting exis-
tence of leptin resistance, at least centrally in the hypo-
thalamus. In contrast, leptin resistance is expected to be
absent from liver, in which chronically elevated leptin
levels may promote NASH by stimulating hepatic triglyc-
eride storage, inﬂammation, and ﬁbrosis (37). Leptin resis-
tance may thus be the basis for hyperleptinemia and
hyperphagia in HFH mice, leading to accelerated weight
and fat gain and consequent adipose tissue dysfunction.
The signiﬁcant heterogeneity in the response to HFD in
C57Bl/6 mice has been previously reported (20,21). The
underlying reason for the large heterogeneity is uncertain
but may be related to copy no. variations in the mouse
genome (50) and perhaps speciﬁcally by differences in the
copy no. of the Ide gene encoding the insulin-degrading
enzyme (51). Alternatively, the variation in phenotype
after HFD may be mediated by epigenetic mechanisms
(21), giving rise to variable adipose expression of speciﬁc
genes. However, the importance of epigenetic mechanisms
in controlling expression of one of these genes was later
discounted (52). Overall, the relative importance of ge-
netic, epigenetic, and environmental factors in the re-
sponse to high-fat feeding in C57Bl/6 mice is still unclear.
In conclusion, we show that a subset of C57Bl/6 mice
fed a HFD composed of palm oil developed NASH. Our
data support the existence of a tight relationship between
adipose tissue dysfunction and NASH pathogenesis and
point to several novel potential predictive biomarkers for
NASH.
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